GSK plc (GSK) ORD GBP0.3125
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
- Add to watchlist
- Create an alert
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
Share news, reports & tips
-
Citi cuts GSK target price after Arexy disappointment, but stays at 'buy'
5 July 2024 08:33
(Sharecast News) - Citi has reiterated its 'buy' rating on GSK despite a flurry of disappointing news for the biopharma giant in recent weeks, though the bank has slashed its target price for the...
-
GSK restructures vaccine collaboration with CureVac
3 July 2024 09:45
(Sharecast News) - GSK announced on Wednesday that it has restructured its collaboration with CureVac into a new licensing agreement, granting GSK exclusive rights to develop, manufacture, and globally...
-
London close: Stocks fall on EU inflation, US jobs data
2 July 2024 17:24
(Sharecast News) - London stocks closed lower on Tuesday as investors digested eurozone inflation data and a modest increase in US job openings.
-
London close: Stocks mixed ahead of key UK, US data
27 June 2024 15:48
(Sharecast News) - London stocks ended Thursday's trading session with a mixed performance as market participants awaited crucial US inflation data and UK GDP figures set to be released later in the week.
-
GSK shares drop as US narrows recommendations for RSV vaccines
27 June 2024 09:58
(Sharecast News) - Shares in biopharma giant GSK tumbled on Thursday after a ruling by a US health agency narrowed usage recommendations for all respiratory syncytial virus (RSV) vaccines, restricting the...
-
GSK reports regulatory progress for Omjjara, Jemperli
24 June 2024 07:21
(Sharecast News) - GSK announced on Monday that it has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for 'Omjjara', or momelotinib, as a treatment for...
-
Zantac litigation fears overdone at GSK, says Shore Capital
11 June 2024 14:31
(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but the long-term investment case is "still...
-
GSK launches appeal to recent Zantac ruling
11 June 2024 07:22
(Sharecast News) - GSK has started the process of appealing a recent decision by the Delaware Superior Court regarding the ongoing Zantac, or ranitidine, litigation, it announced on Tuesday.
-
GSK's Arexvy vaccine approved for wider age range
10 June 2024 07:17
(Sharecast News) - US regulators have approved the use of GSK's Arexvy vaccine for a younger age group, the biopharma group announced on Monday.
-
GSK shares slump as US judge says experts can testify in Zantac cases
3 June 2024 07:30
(Sharecast News) - GSK shares were down almost 10% on Monday after a US court ruled that jury trials could hear expert witnesses in 70,000 cases brought by cancer sufferers claiming its Zantac heartburn drug...
-
London close: Stocks mixed after disappointing retail sales data
24 May 2024 15:19
(Sharecast News) - London stocks closed with mixed results on Friday, influenced by earlier declines in the US and Asian markets, as investors reacted to a larger-than-expected drop in UK retail sales.
-
Jury rules in favour of GSK in Zantac trial
24 May 2024 07:30
(Sharecast News) - A court in Illinois has ruled in favour of GSK in the first Zantac case to go to trial, the UK drugs giant confirmed on Friday.
Company announcements Announcements
-
Director/PDMR Shareholding
16 July 2024 15:30
GSK
-
Director/PDMR Shareholding
15 July 2024 15:30
GSK
-
GSK and CureVac collaboration restructured
3 July 2024 07:00
GSK
-
Total Voting Rights
1 July 2024 15:00
GSK
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.